Literature DB >> 31690291

The shape of the glucose response curve during an oral glucose tolerance test heralds β-cell function in a large Chinese population.

Xinqi Cheng1, Na Yang2, Yuxiu Li2, Qi Sun2, Ling Qiu1, Lingling Xu2, Fan Ping2, Wei Li2, Huabing Zhang3.   

Abstract

BACKGROUND: The shape of the glucose response curve during an oral glucose tolerance test (OGTT) can predict β-cell function and insulin resistance. However, there have been few studies conducted on Chinese people. Thus, we aimed to verify the usefulness of the glucose response curve in a large Chinese population.
METHODS: A total of 9059 OGTT (3-h tests) were categorized into either a monophasic or a multiphasic group based on the shape of the glucose response. Homeostasis model assessments of fasting insulin resistance, the Matsuda Index, the insulinogenic index, and the disposition index were assessed by plasma glucose and serum insulin concentration obtained at fasting or during an OGTT.
RESULTS: The shape of the OGTT glucose response curve was monophasic in 87.3% and multiphasic in 12.7% of participants. Individuals in the multiphasic group were younger compared to those in the monophasic group (38.6 ± 13.6 vs. 35.4 ± 13.5, P < 0.001). Individuals in the monophasic group had significantly higher fasting plasma glucose (FPG 5.6 ± 13.5 vs. 5.2 ± 0.6, P < 0.001), fasting insulin (FINS 14.8 ± 8.7 vs. 13.5 ± 7.9, P < 0.01), and homeostasis model assessment of insulin resistance (HOMA-IR 3.8 ± 2.6 vs. 3.1 ± 2.0, P < 0.001) and impaired β-cell function (disposition index 12.7 ± 14.1 vs. 16.6 ± 17.8, P < 0.001) compared to those in the multiphasic group.
CONCLUSION: The monophasic OGTT glucose response curve could reflect impaired β-cell function in a large Chinese population.

Entities:  

Keywords:  Chinese; Glucose response curve; OGTT

Mesh:

Substances:

Year:  2019        PMID: 31690291      PMCID: PMC6833144          DOI: 10.1186/s12902-019-0446-4

Source DB:  PubMed          Journal:  BMC Endocr Disord        ISSN: 1472-6823            Impact factor:   2.763


Background

Diabetes mellitus (DM) has been categorized as a complex and multifactorial metabolic condition [1]. Many factors play important roles in the development of glucose intolerance in individuals with type 2 diabetes (T2D), such as impaired insulin secretion and insulin resistance [2, 3]. It is widely accepted that the gold standard method for evaluating insulin action is hyperinsulinemic-euglycemic clamp [4]. Because this method is invasive, complicated, and expensive, its application in clinical practice is limited. The oral glucose tolerance test (OGTT) has been used to diagnose diabetes or to capture the impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) based on the fasting plasma glucose (FPG) and 2-h plasma glucose (2hPG) [5]. Although β-cell function and insulin action can be obtained through calculating a series of formulas, such as the insulinogenic index or Matsuda Index during the OGTT, they are not intuitive. The OGTT glucose response curve could be a novel and intuitive biomarker to identify early metabolic risk [6]. Recent cross-sectional studies [6-13] showed that OGTT response curves, either monophasic or biphasic, can not only indicate β-cell function and insulin resistance but also differentiate diabetes risk. Those studies revealed that individuals with a monophasic curve tended to have worse insulin sensitivity and β-cell function. A recent prospective study demonstrated that individuals with a biphasic curve developed T2D at a lower rate than those with a monophasic curve, independent of FPG and/or 2hPG [14]. However, the scale of these studies was generally small, with a maximum of hundreds of subjects included, and only one study was conducted in an Asian population [11]. These studies mainly focused on people without diabetes. No studies showed a relationship between age and the shape of the glucose response curve. In addition, few studies reported the dynamic change of glucose response curves and their relationship with baseline β-cell function and insulin sensitivity. Therefore, the purposes of this study were as follows: 1) to verify the utility of the OGTT glucose response curve in predicting β-cell function and insulin sensitivity in a large Chinese population with varying statuses of glucose tolerance; 2) to examine the relationship between age and the shape of glucose response curves; and 3) to assess if the shape of glucose response curves changed dynamically over time and whether the change was related to baseline β-cell function and insulin sensitivity.

Methods

Subjects

We retrospectively analyzed data of individuals who were tested with a 3-h OGTT and with complete glucose and insulin testing in Peking Union Medical College Hospital from August 2011 to January 2018. Participants were excluded from the study if any of the following criteria were met: a) missing demographic information (age or sex); b) under 18 years old and over 18 years old who did not receive 75 g glucose for OGTT; c) FPG < 3.9 mmol/L; d) history of diabetes; e) FINS > 60 μIU/ml or serum insulin level > 300 μIU/ml at any point of OGTT, because the upper limit was 300 μIU/ml; e) 30-min plasma glucose ≤0-min plasma glucose or 30-min serum insulin ≤0-min serum insulin, to ensure insulinogenic index could be calculated; and g) shapes of the curve could not be classified.

Blood sampling and OGTT

After an overnight fast, participants underwent a 3-h OGTT with the ingestion of 75 g glucose. Venous blood samples were obtained at 0, 30, 60, 120, and 180 min. Plasma glucose was measured by the hexokinase method using a Beckman AU2700 analyzer (Beckman Coulter, Brea, CA, USA). Serum insulin was assessed by chemiluminescence immunoassay using a Siemens ADIVA Centaur XP analyzer (Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA). The glucose and insulin assays were standardized to NIST SRM 965 and WHO 1st IRP 66/304, respectively. The repeatability and within laboratory coefficient variations were < 5%.

Classification of glucose tolerance status

According to the World Health Organization definition [5, 15, 16], normal glucose tolerance (NGT) was defined as FPG < 6.1 mmol/L and 2-h plasma glucose < 7.8 mmol/L. Prediabetes was defined as having IFG (FPG: 6.1–6.9 mmol/L) and/or IGT (2-h plasma glucose: 7.8–11.0 mmol/L). Diabetes was defined as having FPG ≥7.0 mmol/l and/or 2-h plasma glucose ≥11.1 mmol/L.

Classification of glucose curve shapes

The shapes were classified in line with previous studies [17]. A monophasic response curve was determined by a gradual increase in glucose concentrations until a peak was reached, followed by a subsequent decrease in glucose of ≥0.25 mmol/L. A biphasic response curve was defined by the second rise in glucose concentrations of ≥0.25 mmol/L. A triphasic response curve was defined by two complete peaks of the plasma glucose curve, with every rise and decrease in glucose concentrations of ≥0.25 mmol/L. The latter two were collectively called multiphasic response curve. This was done with a plasma glucose threshold of 0.25 mmol/L to minimize fluctuations in glucose concentrations, which may be caused by the method of glucose analysis rather than by physiological reasons.

Calculation of variables

Areas under the glucose and insulin curves were calculated with the trapezoidal rule [10]. Insulin action was estimated by the homeostasis model assessment for insulin resistance (HOMA-IR) and the whole-body insulin sensitivity index of Matsuda. HOMA-IR = (I0-G0)/22.5, with glucose and insulin expressed as mmol/L and mUI/ml, respectively [18]. The Matsuda Index = 10,000/√[(fasting glucose (mg/dl) × FINS (μU/ml)) × (mean glucose (mg/dl) × mean insulin (μU/ml)] [19]. Insulin secretion was estimated by the insulinogenic index. The insulinogenic index was calculated using fasting and 30-min insulin and glucose concentrations [20]. β-cell function was estimated by the disposition index as the product of insulinogenic index and HOMA-IR [21].

Statistical analysis

Summary statistics were calculated using frequencies and proportions for categorical data and means (standard deviations) for continuous variables. Kruskal-Wallis, Pearson χ2, and unpaired Student’s t-tests were used for comparisons. Analysis of covariance was used to compare two glucose response curve groups (monophasic vs. multiphasic) after adjusting for the potential confounding effects (age, sex, glycemic status). A two-sided p-value < 0.05 was considered to indicate statistical significance. All data were analyzed using IBM SPSS Statistics, version 25. The authors have full access to and take full responsibility for the integrity of the data. The manuscript has been read and approved by all the authors.

Results

Baseline characteristics according to glucose curve shapes

A total of 9059 OGTTs in 8391 study individuals were included in the final analysis (Fig. 1). The baseline age was 38.2 ± 13.6 years, and 74.4% were female. In terms of the shape of the participants’ OGTT glucose response curve, 87.3% were monophasic, 6.1% were biphasic, and 6.6% were triphasic. Although the individuals with a triphasic curve had better insulin sensitivity and β-cell function than those with a biphasic curve (Table 1), in view of the limited cases, the triphasic group and the biphasic group were collectively referred to as the multiphasic group. Physical and glucose metabolic characteristics of participants with monophasic and multiphasic curves are presented in Table 1. Figure 2 illustrates the average glucose at each point in the monophasic, biphasic, and triphasic curves. The monophasic group exhibited significantly higher FPG (5.6 ± 13.5 vs. 5.2 ± 0.6), 2hPG (8.2 ± 3.2 vs. 6.3 ± 2.0), fasting serum insulin (FINS), and 2 h serum insulin (2 h INS) than the multiphasic group. The monophasic group had a significantly higher HOMA-IR (3.8 ± 2.6 vs. 3.1 ± 2.0) and lower Matsuda Index (2.9 ± 1.9 vs. 3.8 ± 2.5) and insulinogenic index (25.1 ± 23.0 vs. 16.6 ± 17.8). Disposition index, the indicator of β-cell function, was nearly 42% lower in the monophasic group (Table 1). These differences remained significant after adjusting for sex and age.
Fig. 1

Study Flow Diagram OGTT: oral glucose tolerance test

Table 1

Demographic and metabolic characteristics of 9059 participants with monophasic versus multiphasic OGTT glucose response curve and 1150 participants with biphasic versus triphasic

VariablesMonophasic group(n = 7909)Multiphasic group(n = 1150)P valueBiphasic group(n = 548)Triphasic group(n = 602)P value
Age (years)38.6 ± 13.635.4 ± 13.5< 0.00135.1 ± 13.735.8 ± 13.20.391
Sex (male/female), n%2100 (26.6)/5809 (73.4)219 (19.0)/931 (81.0)< 0.001106 (19.3)/442 (80.7)113 (18.8)/489 (81.2)0.805
FBG (mmol/L)5.6 ± 13.55.2 ± 0.6< 0.0015.2 ± 0.65.2 ± 0.60.189
30 min GLU (mmol/L)9.5 ± 2.08.3 ± 1.6< 0.0018.4 ± 1.68.2 ± 1.6<0.001
2 h GLU (mmol/L)8.2 ± 3.26.3 ± 2.0< 0.0015.4 ± 1.87.2 ± 1.9<0.001
FINS14.8 ± 8.713.5 ± 7.9< 0.00113.2 ± 8.413.7 ± 7.50.328
30 min INS97.7 ± 59.6123.5 ± 67.1< 0.001105.6 ± 62.0139.7 ± 67.5<0.001
2 h INS106.9 ± 66.976.8 ± 57.8< 0.00154.7 ± 43.296.8 ± 62.0<0.001
Glycemic status(%)
 NGT4253 (53.8)903 (78.5)486 (88.7)417 (69.3)
 IFG/IGT/IFG + IGT2362 (29.9)206 (17.9)< 0.00150 (9.1)156 (25.9)<0.001
 DM1294 (16.3)41 (3.6)12 (2.2)29 (4.8)
Glucose AUC (mg·dL −1· h −1)1473.5 ± 437.11181.2 ± 257.8< 0.0011180.0 ± 259.71182.4 ± 256.20.876
Insulin AUC (mg·dL −1· h − 1)16,299.7 ± 8297.513,968.7 ± 7498.6< 0.00113,182.2 ± 7277.714,684.7 ± 7629.90.001
HOMA-IR3.8 ± 2.63.1 ± 2.0< 0.0013.1 ± 2.13.2 ± 1.80.595
Matsuda Index2.9 ± 1.93.8 ± 2.5< 0.0014.0 ± 2.73.6 ± 2.30.018
Insulinogenic index25.1 ± 23.042.9 ± 37.7< 0.00136.0 ± 35.949.1 ± 38.2<0.001
Disposition index12.7 ± 14.116.6 ± 17.8< 0.00113.7 ± 15.419.2 ± 19.4<0.001

Values are reported as the mean ± SD or n (%). FBG fasting blood glucose, 30 min GLU glucose at 30 min, 2 h GLU glucose at 120 min, FINS fasting insulin, 30 min INS insulin at 30 min, 2 h INS insulin at 1200 min, NGT normal glucose tolerance, IFG impaired fasting glucose, IGT impaired glucose tolerance, DM diabetes mellitus, AUC area under the curve

Fig. 2

Glucose during a 3-h OGTT in monophasic, biphasic and triphasic groups among different glycemic status. NGT: normal glucose tolerance, DM: diabetes mellitus

Study Flow Diagram OGTT: oral glucose tolerance test Demographic and metabolic characteristics of 9059 participants with monophasic versus multiphasic OGTT glucose response curve and 1150 participants with biphasic versus triphasic Values are reported as the mean ± SD or n (%). FBG fasting blood glucose, 30 min GLU glucose at 30 min, 2 h GLU glucose at 120 min, FINS fasting insulin, 30 min INS insulin at 30 min, 2 h INS insulin at 1200 min, NGT normal glucose tolerance, IFG impaired fasting glucose, IGT impaired glucose tolerance, DM diabetes mellitus, AUC area under the curve Glucose during a 3-h OGTT in monophasic, biphasic and triphasic groups among different glycemic status. NGT: normal glucose tolerance, DM: diabetes mellitus

Comparison of the glucose curve shapes among different age groups

To explore the relationship between age and the shape of the OGTT curve, we divided age into six categories (Fig. 3). We found that a higher proportion of younger people belonged to the multiphasic group, i.e., a significantly higher proportion of participants aged 18 to 30 years (16.8%) were in the multiphasic group compared with all the other, older groups (30–40 years: 12.2%, 40–50 years: 9.4%, 50–60 years: 9.1%, ≥60 years: 10.7%) (p < 0.001). Furthermore, we divided each age group into three glycemic stages (NGT, prediabetes, DM) to adjust the effect of age on glycemic status (Fig. 3). When participants were in NGT or prediabetes, younger individuals had a higher proportion of multiphasic curves. However, when the glycemic status progressed to diabetes, quite a low percentage of individuals in all age groups had multiphasic curves.
Fig. 3

Proportion of multiphasic curves at different age group and glycemic status NGT: normal glucose tolerance, DM: diabetes mellitus

Proportion of multiphasic curves at different age group and glycemic status NGT: normal glucose tolerance, DM: diabetes mellitus

Types of glucose curve shape as the indicator for insulin resistance and β-cell function

Surrogate markers of insulin sensitivity and β-cell function including HOMA-IR, Matsuda Index, insulinogenic index, and disposition index were significantly different between the monophasic and multiphasic groups (Table 1). After stratification in glycemic status, the difference in insulinogenic index remained significant at every status of glycemic metabolism. However, the other three indexes no longer showed significant differences in individuals with DM. In addition, no significant differences between the two groups were noted for HOMA-IR in participants with prediabetes (Table 2).
Table 2

Demographic and metabolic characteristics of 9059 participants with monophasic versus multiphasic OGTT-glucose response curve in different glycemic status

NGT(n = 5156)Prediabetes(n = 2568)DM(n = 1334)
Monophasic(n = 4253)Multiphasic(n = 903)PMonophasic(n = 2362)Multiphasic(n = 206)PMonophasic(n = 1293)Multiphasic(n = 41)P
Age (years)35.1 ± 12.333.9 ± 12.50.00841.3 ± 13.640.1 ± 15.40.21345.2 ± 13.746.3 ± 13.90.598
Sex (male/female), n%963 (22.6)/3290 (77.4)159 (17.6)/744 (82.4)0.001682 (28.9)/1680 (71.1)53 (25.7)/153 (74.3)0.338455 (35.2)/838 (64.8)7 (17.1)/34 (82.9)0.016
FBG (mmol/L)5.1 ± 0.55.1 ± 0.4< 0.0015.6 ± 0.65.5 ± 0.6< 0.0017.0 ± 1.76.4 ± 1.20.943
30 min (mmol/L)8.5 ± 1.37.9 ± 1.3< 0.0019.9 ± 1.59.3 ± 1.3< 0.00111.9 ± 2.412.0 ± 2.20.962
2hPG (mmol/L)6.1 ± 0.95.6 ± 1.2< 0.0017.8 ± 1.78.8 ± 1.2< 0.00113.8 ± 3.312.6 ± 2.70.017
FINS13.8 ± 8.013.0 ± 7.70.00815.6 ± 8.515.2 ± 8.40.57817.0 ± 10.415.3 ± 8.00.301
30 min INS112.0 ± 61.6124.1 ± 68.0< 0.00191.9 ± 54.4127.9 ± 63.5< 0.00161.7 ± 42.887.9 ± 53.60.003
2 h INS88.1 ± 57.066.7 ± 50.5< 0.001133.8 ± 68.7115.9 ± 67.8< 0.001119.9 ± 73.7100.6 ± 64.30.098

Glucose AUC

(mg·dL −1· h −1)

1197.1 ± 158.01094.1 ± 152.8< 0.0011563.7 ± 163.91398.0 ± 158.4< 0.0012219.0 ± 462.62010.2 ± 368.50.004

Insulin AUC

(mg·dL −1· h − 1)

15,411.0±7733.013,198.7±7054.3< 0.00118,336.3±8582.017,218.6±8506.10.07315,514.8±8888.914,599.2±7349.00.514
HOMA-IR3.2 ± 1.93.0 ± 1.80.0023.9 ± 2.33.7 ± 2.10.1995.4 ± 4.14.4 ± 2.80.138
Matsuda Index3.3 ± 1.94.1 ± 2.6< 0.0012.5 ± 1.62.8 ± 1.50.0042.3 ± 1.82.6 ± 1.40.419
Insulinogenic index33.1 ± 26.646.4 ± 39.6< 0.00119.2 ± 13.532.9 ± 26.7< 0.0019.4 ± 7.813.9 ± 10.3< 0.001
Disposition index15.1 ± 16.017.0 ± 18.20.00111.7 ± 11.716.5 ± 17.0< 0.0016.9 ± 8.57.6 ± 7.10.594

Values are reported as the mean ± SD or n (%). NGT normal glucose tolerance, DM diabetes mellitus, FBG fasting blood glucose, 30 min GLU glucose at 30 min, 2 h GLU glucose at 120 min, FINS fasting insulin, 30 min INS insulin at 30 min, 2 h INS insulin at 1200 min, AUC area under the curve

Demographic and metabolic characteristics of 9059 participants with monophasic versus multiphasic OGTT-glucose response curve in different glycemic status Glucose AUC (mg·dL −1· h −1) Insulin AUC (mg·dL −1· h − 1) Values are reported as the mean ± SD or n (%). NGT normal glucose tolerance, DM diabetes mellitus, FBG fasting blood glucose, 30 min GLU glucose at 30 min, 2 h GLU glucose at 120 min, FINS fasting insulin, 30 min INS insulin at 30 min, 2 h INS insulin at 1200 min, AUC area under the curve

OGTT glucose peak time, nadir time, and insulin peak time in relation to insulin resistant and β-cell function

The multiphasic group could be further divided into two categories by the time when glucose is lowest. The triphasic curve all reached the nadir at 1 h, while the biphasic curve’s nadir time could be 1 h or 2 h. Regarding β-cell function, the curve with a nadir time of 2 h had significantly lower insulinogenic index and disposition index (Table 3). But there was no marked difference between the two groups for the HOMA-IR and Matsuda Index. Early glucose and insulin peak times were all associated with lower HOMA-IR (p < 0.001) and a higher disposition index (p < 0.001) (Tables 4 and 5).
Table 3

Demographic and metabolic characteristics of 1150 participants with OGTT glucose nadir at 60 min versus at 120 min

OGTT glucose nadir at 60 min(n = 688)OGTT glucose nadir at 120 min(n = 462)P
Age (years)35.5 ± 13.235.3 ± 13.80.824
Sex (male/female), n%119 (17.3)/569 (82.7)100 (21.6)/362 (78.4)0.066
FBG (mmol/L)5.2 ± 0.65.2 ± 0.60.069
30 min GLU(mmol/L)8.2 ± 1.68.5 ± 1.60.004
2 h GLU(mmol/L)7.1 ± 2.05.2 ± 1.6<0.001
FINS13.5 ± 7.413.4 ± 8.60.743
30 min INS137.7 ± 67.5102.3 ± 60.6<0.001
2 h INS92.6 ± 61.353.2 ± 42.3<0.001
Glycemic status(%)
 NGT(%)489 (71.1)414 (89.6)
 IFG/IGT/IFG + IGT(%)167 (24.3)39 (8.4)< 0.001
 DM(%)32 (4.7)9 (1.9)
Glucose AUC (mg·dL −1· h −1)1175.3 ± 267.01190.0 ± 243.40.342
Insulin AUC(mg·dL − 1· h − 1)14,349.1 ± 7572.713,402.2 ± 7358.60.036
HOMAIR3.1 ± 1.83.1 ± 2.20.957
Matsuda Index3.8 ± 2.53.8 ± 2.40.670
Insulinogenic index49.7 ± 40.832.7 ± 29.7<0.001
Disposition index18.8 ± 19.013.1 ± 15.3<0.001

Values are reported as the mean ± SD or n (%). FBG fasting blood glucose, 30 min GLU glucose at 30 min, 2 h GLU glucose at 120 min, FINS fasting insulin, 30 min INS insulin at 30 min, 2 h INS insulin at 1200 min, NGT normal glucose tolerance, IFG impaired fasting glucose, IGT impaired glucose tolerance, DM diabetes mellitus, AUC area under the curve

Table 4

Demographic and metabolic characteristics of 9059 participants with OGTT glucose peak at 30 min, 60 min versus 120 min

OGTT glucose peak at 30 min(n = 4599)OGTT glucose peak at 60 min(n = 3912)OGTT glucose peak at 120 min(n = 548)P
Age (years)35.8 ± 12.840.1 ± 13.644.9 ± 14.9<0.001
Sex (male/female), n%974 (21.2)/3625 (78.8)1178 (30.1)/2734 (69.9)167 (30.5)/381 (69.5)<0.001
FBG(mmol/L)5.2 ± 0.65.7 ± 1.16.6 ± 2.0<0.001
30 min GLU(mmol/L)8.8 ± 1.69.8 ± 2.110.6 ± 3.0<0.001
2 h GLU(mmol/L)6.3 ± 1.58.9 ± 2.814.4 ± 4.3<0.001
FINS13.6 ± 7.715.6 ± 9.216.5 ± 10.3<0.001
30 min INS121.8 ± 63.682.0 ± 50.162.6 ± 48.3<0.001
2 h INS85.9 ± 58.8121.5 ± 68.9116.0 ± 73.2<0.001
Glycemic status(%)
 NGT(%)3749 (81.5)1386 (35.4)21 (3.8)
 IFG/IGT/IFG + IGT(%)766 (16.7)1693 (43.3)109 (19.9)< 0.001
 DM(%)84 (1.8)833 (21.3)418 (76.3)
Glucose AUC (mg·dL −1· h −1)1202.6 ± 212.31609.3 ± 385.42163.9 ± 643.5<0.001
Insulin AUC(mg·dL −1· h − 1)15,048.7 ± 7705.217,313.6 ± 8561.214,668.6 ± 8865.8<0.001
HOMAIR3.2 ± 1.94.1 ± 2.84.9 ± 3.9<0.001
Matsuda Index3.4 ± 2.12.6 ± 1.72.8 ± 2.1<0.001
Insulinogenic index36.1 ± 30.018.8 ± 16.215.0 ± 20.9<0.001
Disposition index15.6 ± 16.211.0 ± 12.48.6 ± 12.6<0.001

Values are reported as the mean ± SD or n (%). FBG fasting blood glucose, 30 min GLU glucose at 30 min, 2 h GLU glucose at 120 min, FINS fasting insulin, 30 min INS insulin at 30 min, 2 h INS insulin at 1200 min, NGT normal glucose tolerance, IFG impaired fasting glucose, IGT impaired glucose tolerance, DM diabetes mellitus, AUC area under the curve

Table 5

Demographic and metabolic characteristics of 9059 participants with OGTT insulin peak at 30 min, 60 min versus 120 min

OGTT insulin peak at 30 min(n = 2935)OGTT insulin peak at 60 min(n = 3729)OGTT insulin peak at 120 min(n = 2279)OGTT insulin peak at 180 min(n = 116)P
Age (years)36.1 ± 13.537.9 ± 13.141.3 ± 13.939.7 ± 14.4<0.001
Sex (male/female), n%610 (20.8)/2325 (79.2)1073 (28.8)/2656 (71.2)611 (26.8)/1668 (73.2)25 (21.2)/91 (78.8)<0.001
FBG(mmol/L)5.2 ± 1.05.5 ± 1.05.9 ± 1.26.3 ± 1.6<0.001
30 min GLU(mmol/L)8.6 ± 1.79.4 ± 2.010.1 ± 2.010.2 ± 2.6<0.001
2 h GLU(mmol/L)6.9 ± 2.47.1 ± 2.610.3 ± 3.312.9 ± 4.2<0.001
FINS13.7 ± 7.914.8 ± 8.815.5 ± 8.817.2 ± 11.2<0.001
30 min INS133.0 ± 66.195.4 ± 54.971.3 ± 43.756.4 ± 35.1<0.001
2 h INS85.5 ± 59.789.6 ± 56.4147.2 ± 70.6117.0 ± 62.9<0.001
Glycemic status(%)
 NGT(%)2211 (75.3)2514 (67.4)424 (18.6)7 (5.3)
 IFG/IGT/IFG + IGT(%)549 (18.7)893 (24.0)1089 (47.8)38 (32.7)< 0.001
 DM(%)175 (6.0)322 (8.6)766 (33.6)71 (61.9)
Glucose AUC (mg·dL −1· h −1)1239.8 ± 329.61389.2 ± 362.01738.5 ± 440.92070.4 ± 580.7<0.001
Insulin AUC(mg·dL −1· h − 1)14,403.2 ± 7536.116,046.0 ± 8141.517,980.4 ± 8741.517,006.3 ± 8977.3<0.001
HOMAIR3.3 ± 2.13.7 ± 2.64.2 ± 2.85.1 ± 4.5<0.001
Matsuda Index3.5 ± 2.22.9 ± 1.92.6 ± 1.82.8 ± 2.6<0.001
Insulinogenic index41.8 ± 33.423.9 ± 19.415.1 ± 13.511.7 ± 10.2<0.001
Disposition index17.4 ± 17.612.7 ± 13.59.0 ± 10.76.7 ± 7.1<0.001

Values are reported as the mean ± SD or n (%). FBG fasting blood glucose, 30 min GLU glucose at 30 min, 2 h GLU glucose at 120 min, FINS fasting insulin, 30 min INS insulin at 30 min, 2 h INS insulin at 1200 min, NGT normal glucose tolerance, IFG impaired fasting glucose, IGT impaired glucose tolerance, DM diabetes mellitus, AUC area under the curve

Demographic and metabolic characteristics of 1150 participants with OGTT glucose nadir at 60 min versus at 120 min Values are reported as the mean ± SD or n (%). FBG fasting blood glucose, 30 min GLU glucose at 30 min, 2 h GLU glucose at 120 min, FINS fasting insulin, 30 min INS insulin at 30 min, 2 h INS insulin at 1200 min, NGT normal glucose tolerance, IFG impaired fasting glucose, IGT impaired glucose tolerance, DM diabetes mellitus, AUC area under the curve Demographic and metabolic characteristics of 9059 participants with OGTT glucose peak at 30 min, 60 min versus 120 min Values are reported as the mean ± SD or n (%). FBG fasting blood glucose, 30 min GLU glucose at 30 min, 2 h GLU glucose at 120 min, FINS fasting insulin, 30 min INS insulin at 30 min, 2 h INS insulin at 1200 min, NGT normal glucose tolerance, IFG impaired fasting glucose, IGT impaired glucose tolerance, DM diabetes mellitus, AUC area under the curve Demographic and metabolic characteristics of 9059 participants with OGTT insulin peak at 30 min, 60 min versus 120 min Values are reported as the mean ± SD or n (%). FBG fasting blood glucose, 30 min GLU glucose at 30 min, 2 h GLU glucose at 120 min, FINS fasting insulin, 30 min INS insulin at 30 min, 2 h INS insulin at 1200 min, NGT normal glucose tolerance, IFG impaired fasting glucose, IGT impaired glucose tolerance, DM diabetes mellitus, AUC area under the curve

Change in the OGTT glucose curve shape and risk of impaired glucose metabolism

There were 635 participants who underwent OGTT twice. Table 5 shows baseline physical and metabolic characteristics of all the participants with a stable glucose response curve shape compared to those with unstable shape. Of the participants, 80.3% exhibited no change in shape between the baseline and the second OGTT (Table 6). Individuals who maintained a monophasic glucose response curve had the lowest rate of NGT, and those who maintained a multiphasic glucose response curve had the highest rate of NGT at baseline. Individuals with a stable monophasic glucose response shape had significantly higher fasting and 2hPG. Persistence of the monophasic shape was, in general, associated with worse insulin sensitivity and reduced β-cell function. Individuals whose glucose response curve changed from multiphasic to monophasic tended to have a higher rate of deterioration in glucose metabolism (Table 7).
Table 6

Demographic and metabolic characteristics of 502 participants with stable versus unstable OGTT-glucose response curve

StableUnstableP value
MonophasicMultiphasicMonophasic to MultiphasicMultiphasic to Monophasic
N37195567
Age (years)35.5 ± 12.337.0 ± 11.332.9 ± 13.235.1 ± 14.60.535
Sex (male/female, %)62 (16.7)/309 (83.3)2 (22.2)/7 (77.8)9 (16.4)/46 (83.6)9 (13.4)/58 (86.6)0.878
FBG(mmol/L)5.6 ± 0.95.1 ± 0.65.2 ± 0.65.2 ± 0.5< 0.001
30 min GLU(mmol/L)9.2 ± 1.78.2 ± 1.48.5 ± 1.38.3 ± 1.4< 0.001
2 h GLU(mmol/L)8.1 ± 2.75.6 ± 1.26.5 ± 1.66.5 ± 1.7< 0.001
FINS17.7 ± 9.211.1 ± 5.315.4 ± 10.016.8 ± 9.70.075
30 min INS111.2 ± 65.3152.8 ± 69.7131.2 ± 74.8150.2 ± 67.7< 0.001
2 h INS128.8 ± 72.269.3 ± 46.7101.7 ± 66.997.0 ± 65.7< 0.001
Glycemic status(n,%)
 NGT181 (48.8)9 (100)42 (76.4)51 (76.1)
 IFG/IGT/IFG + IGT145 (39.1)012 (21.8)16 (23.9)< 0.001
 DM45 (12.1)01 (1.8)0

Glucose AUC

(mg·dL −1· h −1)

1461.3 ± 366.01100.2 ± 83.11230.5 ± 231.01184.8 ± 208.6< 0.001

Insulin AUC

(mg·dL −1· h − 1)

19,184.5 ± 8734.113,817.2 ± 5128.217,677.0 ± 90,944.718,637.6 ± 8730.20.068
HOMA-IR4.4 ± 2.62.6 ± 1.23.6 ± 2.43.9 ± 2.30.012
Matsuda Index2.4 ± 1.63.8 ± 2.33.1 ± 2.03.1 ± 2.0< 0.001
Insulinogenic index29.6 ± 28.352.8 ± 34.137.7 ± 23.755.2 ± 56.7< 0.001
Disposition index17.2 ± 17.316.3 ± 7.019.2 ± 18.224.3 ± 20.40.025

Values are reported as the mean ± SD or n (%). FBG fasting blood glucose, 30 min GLU glucose at 30 min, 2 h GLU glucose at 120 min, FINS fasting insulin, 30 min INS insulin at 30 min, 2 h INS insulin at 1200 min, NGT normal glucose tolerance, IFG impaired fasting glucose, IGT impaired glucose tolerance, DM diabetes mellitus, AUC area under the curve

Table 7

The relationship between the change of the phase number and the change of the glycemic status

Glycemic statusImproveUnchangingAggravationTotal
Change of the phase-numberDecrease7 (10.4%)49 (73.1%)11 (16.4%)67
Unchanging65 (17.1%)245 (64.5%)70 (18.4%)380
Increase11 (20.0%)38 (69.1%)6 (10.9%)55
Total8333287502

Values are reported as N (n%)

Demographic and metabolic characteristics of 502 participants with stable versus unstable OGTT-glucose response curve Glucose AUC (mg·dL −1· h −1) Insulin AUC (mg·dL −1· h − 1) Values are reported as the mean ± SD or n (%). FBG fasting blood glucose, 30 min GLU glucose at 30 min, 2 h GLU glucose at 120 min, FINS fasting insulin, 30 min INS insulin at 30 min, 2 h INS insulin at 1200 min, NGT normal glucose tolerance, IFG impaired fasting glucose, IGT impaired glucose tolerance, DM diabetes mellitus, AUC area under the curve The relationship between the change of the phase number and the change of the glycemic status Values are reported as N (n%)

Discussion

The present investigation revealed the following findings regarding the shape of OGTT curve in a large Chinese population: 1) multiphasic OGTT response curves were not rare in Chinese people, accounting for more than 10% of the population; 2) monophasic curves were more common in older people and in those with worse glycemic status; 3) individuals with monophasic curves had poorer β-cell function than individuals with multiphasic curves, despite having similar glycemic status; 4) individuals who were in NGT with a monophasic shape showed significantly worse insulin sensitivity, as reflected by the HOMA-IR and Matsuda Index, compared to patients with a multiphasic curve; 5) β-cell function was better in patients whose glucose concentration started to decrease at 60 min compared to later among the multiphasic curve group; and 6) the number of phases of the same subject could change at different times, and the number of phases increased with the improvement of glucose status. In studies of nondiabetic individuals, the morphology of the monophasic glucose response curve is the dominant phenotype, up to 57–84% in adults [12, 13, 17, 22, 23] and 35–69% in obese youth at high risk for T2D [6, 7, 9, 10, 24]. Our study showed that about 88.3% of individuals had monophasic response curves and 11.7% had multiphasic response curves. Combining our present research with previous studies in youth [6, 10] and adults [12], the multiphasic group tends to be associated with younger age compared with the monophasic group. Our study further found that there was little difference between the two glucose curve shape groups when the glycemic status reached diabetes, and both young and old individuals had an extremely low proportion of multiphasic OGTT response curve. Cross-sectional studies in youths [6-13] and adults [11–13, 23] showed that the shape of the OGTT glucose response curve could indicate insulin sensitivity and β-cell function, as well as differentiate type 2 diabetes risk. Obese youths with monophasic glucose response curves were worse in both hepatic and peripheral insulin sensitivity measured by the clamp method compared with the biphasic group, as well as in β-cell function, which was indicated by impaired disposition index as a result of lacking in a compensatory increase in first and second-phase insulin secretion [6]. Evidence from patients with suspected gestational diabetes who underwent 3 h OGTT showed that a greater number of phases in the OGTT glucose response curve was associated with a healthier metabolic state, which suggests that a biphasic response curve may be associated with a lower incidence of prediabetes and T2D [13]. In our study, β-cell function was better in individuals with multiphasic glucose response curve. As for insulin sensitivity, the difference was still significant in the NGT group, but the difference did not remain significant in the diabetes group. The most likely reason is that defects in β-cell function are more severe in Chinese patients with diabetes than those in Europeans or Americans, resulting in more serious deficiencies in insulin secretion [25]. Am American study conducted in adult patients showed that the baseline and subsequent glucose concentrations in the OGTT could stratify the risk for progression to T2D; that is, a faster return to the FPG concentration may suggest a lower risk of T2D [22]. Our study further found that individuals with multiphasic curves whose plasma glucose concentration reached the lowest point at 60 min had better β-cell function than those with a nadir at 120 min. Consistent with previous studies [26], we found that the earlier the glucose/insulin peak in the OGTT curve, the better the β-cell function. Our data showed that individuals whose response glucose curve changed from multiphasic to monophasic during follow-up were more prone to deteriorate in glycemic status than those whose glucose response curves changed from monophasic curves to multiphasic curves. This result is supported by several longitudinal studies. A 7–8 year longitudinal study demonstrated that pre-diabetic patients with monophasic curves had twice the incidence of diabetes as those with biphasic curves, despite similar fasting and 2hPG concentrations [22]. Individuals with a monophasic curve at baseline and those whose patterns changed from biphasic to monophasic had an increased risk for impaired glucose metabolism [14]. We also found that individuals with a persistent monophasic curve had worse insulin sensitivity and β-cell function than those with other forms at baseline. The strengths of the present investigation include the following: 1) it is the first large-scale (up to 10,000) investigation of the relationship between the OGTT glucose response curve and insulin resistance/β-cell function in Chinese people; 2) the study included people with different glucose metabolic states and across different age groups. Potential perceived limitations would be that we have no anthropometric data, such as body mass index (BMI) and waist circumference, which could have an influence on glycemic status. But previous research showed that the OGTT response curve shape remained strongly associated with insulin sensitivity and β-cell function after adjusting for BMI, blood pressure, and waist circumference [6, 8]. In addition, our research follows the standard methods used in China. The OGTT glucose response curve shape was determined by data only at 0, 30, 60, 120, and 180 min, lacking 90 min glucose data, which may have led to an underestimation in the phase of the curve. Investigations of the change in patterns or shapes of the OGTT glucose response curves did not have regular follow-up.

Conclusions

In summary, the present study is the first to demonstrate that in a large Chinese population, the monophasic OGTT glucose response curve was associated with reduced β-cell function, higher HOMA-IR, and older age. However, prospective longitudinal studies are needed to verify the usefulness of the OGTT glucose response curve in predicting progression to prediabetes or T2D in Chinese. Further, it remains essential to examine whether any factors could shift the OGTT glucose response curve from monophasic to multiphasic.
  25 in total

1.  Assessing the shape of the glucose curve during an oral glucose tolerance test.

Authors:  Otto Tschritter; Andreas Fritsche; Fatemeh Shirkavand; Fausto Machicao; Hans Häring; Michael Stumvoll
Journal:  Diabetes Care       Date:  2003-04       Impact factor: 19.112

2.  Beyond the morphology of the glucose curve following an oral glucose tolerance test in obese youth.

Authors:  Giuseppe Nolfe; Maria Rita Spreghini; Rita Wietrzycowska Sforza; Giuseppe Morino; Melania Manco
Journal:  Eur J Endocrinol       Date:  2011-10-18       Impact factor: 6.664

3.  The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes.

Authors:  Heba M Ismail; Ping Xu; Ingrid M Libman; Dorothy J Becker; Jennifer B Marks; Jay S Skyler; Jerry P Palmer; Jay M Sosenko
Journal:  Diabetologia       Date:  2017-09-27       Impact factor: 10.122

4.  [The monophasic pattern in oral glucose tolerance test as a predictive risk factor of type 2 diabetes in obese paediatric patients].

Authors:  Aura D Herrera-Martínez; Patricia Enes; María Martín-Frías; Belén Roldán; Rosa Yelmo; Raquel Barrio
Journal:  An Pediatr (Barc)       Date:  2017-04-17       Impact factor: 1.500

Review 5.  Euglycaemic glucose clamp: what it can and cannot do, and how to do it.

Authors:  Tim Heise; Eric Zijlstra; Leszek Nosek; Sascha Heckermann; Leona Plum-Mörschel; Thomas Forst
Journal:  Diabetes Obes Metab       Date:  2016-07-13       Impact factor: 6.577

6.  Insulin secretory response of diabetics during the period of improvement of glucose tolerance to normal range.

Authors:  K Kosaka; R Hagura; T Kuzuya; N Kuzuya
Journal:  Diabetologia       Date:  1974-12       Impact factor: 10.122

Review 7.  Mechanism of Generation of Oxidative Stress and Pathophysiology of Type 2 Diabetes Mellitus: How Are They Interlinked?

Authors:  Kanwal Rehman; Muhammad Sajid Hamid Akash
Journal:  J Cell Biochem       Date:  2017-05-31       Impact factor: 4.429

8.  The shape of the plasma glucose curve during an oral glucose tolerance test as an indicator of Beta cell function and insulin sensitivity in end-pubertal obese girls.

Authors:  L Bervoets; A Mewis; G Massa
Journal:  Horm Metab Res       Date:  2014-12-15       Impact factor: 2.936

9.  The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test: Forerunner of Heightened Glycemic Failure Rates and Accelerated Decline in β-Cell Function in TODAY.

Authors:  Silva Arslanian; Laure El Ghormli; Joon Young Kim; Fida Bacha; Christine Chan; Heba M Ismail; Lorraine E Levitt Katz; Lynne Levitsky; Jeanie B Tryggestad; Neil H White
Journal:  Diabetes Care       Date:  2018-11-19       Impact factor: 19.112

10.  Glucose response curve and type 2 diabetes risk in Latino adolescents.

Authors:  Joon Young Kim; Dawn K Coletta; Lawrence J Mandarino; Gabriel Q Shaibi
Journal:  Diabetes Care       Date:  2012-06-29       Impact factor: 19.112

View more
  5 in total

1.  Changes in OGTT-derived biomarkers in response to lifestyle intervention among Latino adolescents with obesity.

Authors:  Armando Peña; Joon Young Kim; Jessica A Reyes; Kiley B Vander Wyst; Stephanie L Ayers; Micah L Olson; Allison N Williams; Gabriel Q Shaibi
Journal:  Pediatr Obes       Date:  2021-11-03       Impact factor: 4.000

2.  OGTT Glucose Response Curves, Insulin Sensitivity, and β-Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve β-Cell Function.

Authors:  Silva A Arslanian; Laure El Ghormli; Joon Young Kim; Ashley H Tjaden; Elena Barengolts; Sonia Caprio; Tamara S Hannon; Kieren J Mather; Kristen J Nadeau; Kristina M Utzschneider; Steven E Kahn
Journal:  Diabetes Care       Date:  2021-01-12       Impact factor: 19.112

3.  Personalized computational model quantifies heterogeneity in postprandial responses to oral glucose challenge.

Authors:  Balázs Erdős; Bart van Sloun; Michiel E Adriaens; Shauna D O'Donovan; Dominique Langin; Arne Astrup; Ellen E Blaak; Ilja C W Arts; Natal A W van Riel
Journal:  PLoS Comput Biol       Date:  2021-03-31       Impact factor: 4.475

4.  Shape of the OGTT glucose response curve: relationship with β-cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin.

Authors:  Kristina M Utzschneider; Naji Younes; Neda Rasouli; Joshua I Barzilay; Mary Ann Banerji; Robert M Cohen; Erica V Gonzalez; Faramarz Ismail-Beigi; Kieren J Mather; Philip Raskin; Deborah J Wexler; John M Lachin; Steven E Kahn
Journal:  BMJ Open Diabetes Res Care       Date:  2021-09

Review 5.  The Oral Glucose Tolerance Test: 100 Years Later.

Authors:  Ram Jagannathan; João Sérgio Neves; Brenda Dorcely; Stephanie T Chung; Kosuke Tamura; Mary Rhee; Michael Bergman
Journal:  Diabetes Metab Syndr Obes       Date:  2020-10-19       Impact factor: 3.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.